ANV-419 is under clinical development by Anaveon and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 10% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ANV-419’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ANV-419 is under development for the treatment of solid tumors including metastatic melanoma, kidney cancer, lung cancer, renal cell carcinoma, non-small cell lung cancer, hepatocellular carcinoma, pancreatic cancer, colorectal cancer, esophageal cancer, adenoid cystic carcinoma, relapsed and refractory multiple myeloma. The therapeutic candidate is a rationally7 engineered fusion protein . It acts by targeting interleukin-2 receptor alpha chain (CD25 antigen). It is administered through intravenous route.
Anaveon, is a biopharmaceutical company that transforms engineered cytokines into novel life-saving treatments. The company is headquartered in Switzerland.
For a complete picture of ANV-419’s drug-specific PTSR and LoA scores, buy the report here.